The Total Return for Zhejiang Shouxiangu Pharmaceutical (SHSE:603896) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
The Total Return for Zhejiang Shouxiangu Pharmaceutical (SHSE:603896) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
While Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHSE:603896) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 26% in the last quarter. While that's not great, the returns over five years have been decent. The share price is up 41%, which is better than the market return of 40%.
尽管浙江寿仙谷药业有限公司(SHSE: 603896)的股东们可能普遍感到高兴,但该股最近的表现并不特别好,上个季度股价下跌了26%。虽然这不太好,但五年来的回报还是不错的。股价上涨了41%,好于40%的市场回报率。
Since the long term performance has been good but there's been a recent pullback of 7.4%, let's check if the fundamentals match the share price.
由于长期表现良好,但最近回调了7.4%,因此让我们检查一下基本面是否与股价相符。
Check out our latest analysis for Zhejiang Shouxiangu Pharmaceutical
查看我们对浙江寿仙谷药业的最新分析
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
不可否认的是,市场有时是有效的,但价格并不总是能反映基本的业务表现。通过比较每股收益(EPS)和股价随时间推移的变化,我们可以了解投资者对公司的态度如何随着时间的推移而变化。
Over half a decade, Zhejiang Shouxiangu Pharmaceutical managed to grow its earnings per share at 22% a year. This EPS growth is higher than the 7% average annual increase in the share price. So one could conclude that the broader market has become more cautious towards the stock.
在过去的五年中,浙江寿仙谷药业设法将其每股收益增长到每年22%。每股收益的增长高于股价年均增长7%。因此,人们可以得出结论,整个市场对该股变得更加谨慎。
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
你可以在下面看到 EPS 是如何随着时间的推移而发生的变化(点击图片发现确切的数值)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240109/0-399f3dee31b41e5b4257071796973de9-0-1ddb4ba9d59544ccf7cfbbc95a8edf1c.png/big)
We know that Zhejiang Shouxiangu Pharmaceutical has improved its bottom line lately, but is it going to grow revenue? This free report showing analyst revenue forecasts should help you figure out if the EPS growth can be sustained.
我们知道浙江寿仙谷药业最近提高了利润,但它会增加收入吗?这份显示分析师收入预测的免费报告应帮助您弄清楚每股收益的增长是否可以持续。
What About Dividends?
那股息呢?
It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Zhejiang Shouxiangu Pharmaceutical, it has a TSR of 47% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!
重要的是要考虑任何给定股票的股东总回报率和股价回报率。股东总回报率包含任何分拆或贴现资本筹集的价值,以及任何股息,前提是股息是再投资的。可以说,股东总回报率更全面地描述了股票产生的回报。就浙江寿仙谷药业而言,其股东回报率在过去5年的股东回报率为47%。这超过了我们之前提到的其股价回报率。这在很大程度上是其股息支付的结果!
A Different Perspective
不同的视角
We regret to report that Zhejiang Shouxiangu Pharmaceutical shareholders are down 27% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 11%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 8%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Zhejiang Shouxiangu Pharmaceutical better, we need to consider many other factors. Take risks, for example - Zhejiang Shouxiangu Pharmaceutical has 2 warning signs (and 1 which is a bit unpleasant) we think you should know about.
我们遗憾地报告,浙江寿仙谷药业的股东今年下跌了27%(甚至包括股息)。不幸的是,这比整个市场11%的跌幅还要严重。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。长期投资者不会那么沮丧,因为他们本可以在五年内每年赚8%。最近的抛售可能是一个机会,因此可能值得查看基本面数据以寻找长期增长趋势的迹象。长期跟踪股价表现总是很有意思的。但是,要更好地了解浙江寿仙谷药业,我们需要考虑许多其他因素。例如,冒险吧——浙江寿仙谷药业有两个警告信号(还有一个有点不愉快),我们认为你应该知道。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
如果你想看看另一家公司——一家财务状况可能优异的公司——那么千万不要错过这份已经证明自己可以增加收益的公司的免费名单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报率。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。